ÂÜÀòÂÒÂ×

Inés Moreno Jiménez, PhD has a diverse work experience. Inés began their career in 2011 as a Laboratory Technician Assistant at the Hospital Clínic de Barcelona Molecular Genetics Laboratory, Physiology Department. In 2012, they completed an MSc Internship at Linkoping University, where they worked on a collaboration project between Linkoping and Cranfield University to optimize biomaterial for single cell delivery for cardiac repair. That same year, they also obtained a Master in Research in Stem Cell and Regenerative Medicine from the University of Southampton, where they also worked as a PhD student from 2012-2015. During their PhD, they developed an in vivo model to study human bone regeneration. From 2017-2020, they worked at the Max Planck Institute of Colloids and Interfaces as an Independent Researcher and Scientific Coordinator & Postdoctoral Researcher. During their time at the Institute, they envisioned and brought a project to life in collaboration with Universitätsklinikum Würzburg and led a team of three members. Inés also trained and mentored students and employers to successfully achieve project goals. From 2017-2020, they also worked at QUT (Queensland University of Technology) as a Postdoctoral Researcher, where they coordinated a multidisciplinary research team to complete in vitro and in vivo studies. In 2020, they joined Aortyx as a Senior Research Scientist and Research Scientist. Currently, they are working as a Project Manager at Accure Therapeutics.

Inés Moreno Jiménez, PhD obtained their Bachelor of Biotechnology from Universitat de Lleida in 2012. Inés then went on to receive a Master of Science in Nanomedice from Cranfield University in 2012. In 2013, they completed a Master in Research in Stem Cells and Regenerative Medicine from the University of Southampton. In 2016, they earned their Doctor of Philosophy in Stem Cells and Regenerative Medicine from the University of Southampton. Inés is currently enrolled in a Drug Development program at UC San Diego and a Design and Interpretation of Clinical Trials program at The Johns Hopkins University, both of which are expected to be completed in 2022. In April 2022, they obtained a Good Clinical Practise (GCP) IHC Guidelines certification from The Global Health Network.